Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioFocus Signs Agreement with Aviva Investors

Published: Thursday, September 05, 2013
Last Updated: Thursday, September 05, 2013
Bookmark and Share
Pre-let agreement for construction of new laboratory and HQ building at Chesterford Research Park.

BioFocus and Aviva Investors have announced the signing of a pre-let agreement for the new Robinson Building, a 60,000 square foot (5,587square metres) facility at Chesterford.

BioFocus will unite the majority of its drug discovery groups within the new complex, affording the company a unique position amongst CROs for support of integrated projects.

Chris Newton of BioFocus explains the decision to move: “BioFocus has been expanding its research activities at Chesterford Park, bringing our expertise in different areas such as structural biology, complex cell assays, and medicinal chemistry closer together. Moving many of these teams into a single, modern and efficient building is an important step forward for the company and will bring added synergies to both our business model and to our scientists.”

Julian Cobourne, Asset Manager for Aviva Investors says: “Chesterford Research Park has provided significant support to BioFocus in meeting its property needs over the years and it has been great to work with them to design a much more efficient laboratory building to meet their future requirements.”

Martin Sylvester of Churchmanor Estates (the joint development partner of Aviva Investors at Chesterford Research Park) commented: “This is great news for Chesterford Research Park and also for the South Cambridge life sciences cluster. Aside from the AstraZeneca deal, this is the largest pre-let in the Cambridge area since 2011 and represents a very significant investment in the region’s economy.”

As the Robinson Building already has outline planning permission, construction is expected to start on site almost immediately.

The building has been designed as two wings, linked by an impressive two-storey atrium and a landscaped courtyard. It has an attractive curved profile which will be enhanced by extensive green landscaping.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioFocus Signs Integrated Drug Discovery Collaboration with Boehringer Ingelheim
Under the terms of the agreement, BioFocus will apply its drug discovery services to an undisclosed target within Boehringer Ingelheim’s drug discovery portfolio.
Thursday, November 21, 2013
BioFocus Launches Academic Engagement Initiative
Aim of the initiative is to identify the best new therapeutic strategy ideas from academic groups.
Wednesday, May 01, 2013
BioFocus Achieves Milestone in its Drug Discovery Collaboration with UCB
Discovery milestone triggers payment from UCB and demonstrates BioFocus’ ability to support its clients.
Tuesday, December 04, 2012
BioFocus and Argenta Announce Drug Discovery Collaboration
Collaboration with AstraZeneca in respiratory and inflammatory disease.
Thursday, March 15, 2012
Argenta and BioFocus Announce Two-Year Extension Of Drug Discovery Collaboration with Genentech
Total potential value of the contract extension is up to £21.5 million (€23.4 million).
Monday, August 22, 2011
BioFocus and InterMed Discovery Announce Marketing Collaboration
IMD will make natural product screening libraries available and provide follow-on services to BioFocus.
Wednesday, July 20, 2011
BioFocus Extends Collaboration with Usher III Initiative
BioFocus will further advance the project with the objective of delivering a pre-clinical candidate.
Wednesday, June 22, 2011
Ono and BioFocus Sign Target Discovery Agreement in the Field of Autoimmune Disease
Under the agreement, BioFocus will receive research funding and success payments based on the progress of the collaboration.
Wednesday, January 12, 2011
BioFocus Extends Collaboration with Amgen into 2012
BioFocus has announced that it has extended its contract with Amgen for 2011 and 2012, with an expansion to include target discovery and validation services.
Friday, December 17, 2010
BioFocus and the National Cancer Institute Sign Compound Management Agreement
BioFocus will provide compound management services to NCI for a base period of three years for a total of up to $5 million.
Wednesday, October 13, 2010
BioFocus and Usher III Initiative, Inc. Announce Collaboration
Under the agreement, BioFocus will perform an integrated program encompassing medicinal chemistry and biological sciences.
Thursday, September 09, 2010
BioFocus Renews French Research Tax Credit Accreditation
The accreditation allows eligible French companies to benefit from significant tax relief on research carried out by BioFocus on their behalf until 2013.
Wednesday, June 09, 2010
BioFocus to Host Free Webinar on “Unleashing the Power of Computational Chemistry in Hit Finding Campaigns”
Attendees will learn how computational chemistry tools enable cost- and time-efficient HTS campaigns.
Friday, May 07, 2010
BioFocus Launches Four Compound Libraries Targeting Kinases and Protein-protein Interactions
BioFocus, a leading provider of gene-to-clinical candidate drug discovery services, has announced the launch of four biologically targeted libraries. These new libraries contain novel, drug-like compounds that specifically target kinases and protein-protein interactions.
Tuesday, May 04, 2010
BioFocus Announces its Free Educational Webinars for Drug Discovery Researchers - “Focus on Permeability”
The webinar will guide scientists in the implementation of ADME assays in early drug discovery, and on how best to use the data obtained.
Tuesday, April 27, 2010
Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!